Zydus Receives USFDA EIR with VAI Status for Vadodara Facility

has received the Establishment Inspection Report (EIR) from the USFDA for its API plant in Dabhasa, Vadodara, after an inspection conducted between April 21 and April 25, 2025. The facility has been classified as "Voluntary Action Indicated" (VAI), suggesting that while certain observations were made, they are not severe enough to warrant regulatory enforcement action. The FDA has officially marked the inspection as “closed.” It’s important to note that a VAI classification does not imply full clearance or guarantee reversal of any prior warning letters or alerts unless specifically communicated by the regulator. Nonetheless, the closure of the inspection indicates that the site remains operational under FDA oversight, and any further implications will depend on the company’s response and future inspections. Follow me for more such posts, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.